DailyMed
Cure8 regulatory brief
DailyMed label update for AVSOLA
Medications
Infliximab
Anti-TNF
Biosimilars
Immunomodulators
Regulatory Update
Adult patients
Pediatric Patients
Why This Matters
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide testing and monitoring before and during treatment.
Who Should Pay Attention
Adult and pediatric patients with Crohn's disease or ulcerative colitis (≥6 years), caregivers of pediatric patients, clinicians prescribing biologics, and patients taking concomitant immunomodulators.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Source depthMetadata only
What To Know
This label update summarizes safety warnings, approved uses, and dosing for AVSOLA (infliximab‑axxq).
It reiterates the need for TB and hepatitis B screening before starting therapy, cautions about serious infections and malignancy risk with TNF blockers, and provides adult and pediatric dosing regimens and administration precautions (IV infusion over at least 2 hours).
If you or a caregiver are considering or currently receiving infliximab‑based therapy, this label update is relevant because it restates monitoring and safety steps clinicians should follow and lists the approved age ranges and indications.
Keep In Mind
This is an official prescribing-label (DailyMed) update summarizing approved indications, dosing, and safety warnings; it is regulatory material for clinicians and does not replace individualized medical advice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedJul 29, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
DailyMed label update for INFLECTRA
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...